Abstracts tagged "Biomarkers"

Abstract Number: 1728 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma
Claudia Macaubas¹, Emily Mirizio², Kaila Schollaert-Fitch³, Elizabeth D. Mellins⁴ and Kathryn S. Torok³, ¹Department of Pediatrics, Program in Immunology, Stanford University Med Ctr, Stanford, CA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Dept of Pediatrics CCSR, Stanford University Med Ctr, Stanford, CA
Background/Purpose: Localized scleroderma (LS) has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The understanding of the pathophysiology…
Abstract Number: 2435 • 2017 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Biomarkers of Cardiovascular Disease in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja¹, Patricia Ruiz-Limon², Ivan Arias de la Rosa², Maria Carmen Abalos-Aguilera², Yolanda Jiménez-Gómez¹, Rafaela Ortega-Castro¹, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras², Raquel Lopez-Mejías³, Miguel Angel González-Gay³ and Carlos Perez-Sanchez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Extracellular microRNAs, circulating in the bloodstream and extracellular space, have been proposed as attractive candidates as both diagnostic and prognostic biomarkers in various diseases,…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…
Abstract Number: 714 • 2017 ACR/ARHP Annual Meeting
Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Paula Harvey³, Shadi Akhtari³, Jiandong Su⁴ and Murray Urowitz², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Antimalarial (AM)-induced cardiomyopathy (AMIC) has been rarely reported in systemic lupus erythematosus (SLE). However, given the large number of patients treated, it seems possible…
Abstract Number: 1208 • 2017 ACR/ARHP Annual Meeting
Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI: An Exploratory Study
Johanne Martel-Pelletier¹, Jean-Pierre Raynauld¹, François Mineau¹, François Abram², Patrice Paiement³, Philippe Delorme³ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³ArthroLab Inc., Montreal, QC, Canada
Background/Purpose: There is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in…
Abstract Number: 1844 • 2017 ACR/ARHP Annual Meeting
Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroder⁵, Brian Kabat⁵, Peter A. Merkel⁶, Carol A. Langford⁷, Gary S. Hoffman⁸, Cees G.M. Kallenberg⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene St. Clair¹², John H. Stone¹³, Ulrich Specks¹⁴ and Paul A. Monach¹⁵, ¹Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Department of Medicine, Duke University Medical Center, Durham, NC, ¹³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Boston University School of Medicine, Boston, MA
Background/Purpose: To evaluate serum cytokine and chemokine profiles in patients with ANCA-associated vasculitis (AAV) classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or…
Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Cristina Arriens¹, Rufei Lu², Teresa Aberle², Stan Kamp², Wade DeJager², Melissa E. Munroe², Eliza Chakravarty¹, Katherine Thanou², Joan T. Merrill³, Joel M. Guthridge⁴ and Judith A. James³, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…
Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Helena Enocsson¹, Alf Kastbom¹, Tanja Lukic¹, Christopher Sjöwall², Thomas Skogh¹ and Jonas Wetterö¹, ¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Gabriela Riemekasten¹, Elise Siegert² and Harald Heidecke³, ¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, ²Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany, ³CellTrend GmbH Luckenwalde, Luckenwalde, Germany
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…
Abstract Number: 1210 • 2017 ACR/ARHP Annual Meeting
Non-Responders to Total Joint Replacement Therapy in Osteoarthritis Patients and Novel Metabolic Markers
Guangju Zhai¹, Ming Liu², Quan Li¹, Andrew Furey¹, Weidong Zhang³, Sergei Likhodi¹, Edward Randell¹ and Proton Rahman⁴, ¹Memorial University of Newfoundland, St. John's, NF, Canada, ²Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Jilin University, Changchun, China, ⁴Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, and is the major source of joint pain and disability. The aim of the study…
Abstract Number: 1848 • 2017 ACR/ARHP Annual Meeting
NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis (TA) and Relationship with Disease Activity
Ramnath Misra¹, Avinash Jain², Dinesh Kumar³, Durga Prasanna Misra⁴, Anupam Guleria⁵, Sandeep Kumar⁴, Atul Rawat³, Smriti Chaurasia⁴, Umesh Kumar⁶, Abhishek Zanwar⁴, Durgesh Dubey⁷, Ruchika Goel⁸, Debashish Danda⁹ and Paul Bacon¹⁰, ¹Clinical Immunology, Sanjay Gandhi Postgraduate of Medical Sciences, Lucknow, India, ²Clinical Immunology, Senior Resident, Lucknow, India, ³Centre for Biomedical Research, Lucknow, India, ⁴Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁵Centre for Biomedical Research, DST-INSPIRE Faculty, Lucknow, India, ⁶Centre for Biomedical Research, Research Scholar, Lucknow, India, ⁷Centre for Biomedical Research, PhD Student, Lucknow, India, ⁸Rheumatology, Christian Medical College, Vellore Tamilnadu, India, ⁹Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹⁰Rheumatology, Emeritus Professor, Birmingham, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis of unknown pathogenesis. The current serological and radiological parameters used to assess disease activity are not…
Abstract Number: 2641 • 2017 ACR/ARHP Annual Meeting
Immune Complex-Driven Neutrophil Activation in Systemic Lupus Erythematosus – Novel Biomarkers of Disease Activity and Severity
Hsin-Hsuan Juo¹, Edward Chiou², Keith B. Elkon³ and Christian Lood⁴, ¹Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Department of Medicine & Immunology, University of Washington, Seattle, WA, ⁴Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation is linked to inflammation and autoimmune diseases, including systemic lupus erythematosus (SLE) where nucleic acid-containing immune complexes (ICs) drive inflammation through engagement…
Abstract Number: 460 • 2017 ACR/ARHP Annual Meeting
Usefullness of Serum Angiogenic and Proinflammatory Cytokines to Discriminate between 6 Sets of Remission Criteria and Biomarkers of Radiographic Progression and Clinical Flare in RA in Clinical Remission. Pre-Eliminary Results of a Study of 5 Years of Follow-up
Julio Ramírez¹, Andrea Cuervo², Raquel Celis³, Virginia Ruiz-Esquide¹, M. Victoria Hernández⁴, Raimon Sanmarti⁵ and Juan D. Cañete⁶, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology, Arthritis Unit, Barcelona, Spain, ⁴Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁶Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: The primary aim of this study was to analyse serum levels differences of angiogenic and inflammatory biomarkers between SDAI, CDAI, ACR, DAS28 and sonographic…
Abstract Number: 740 • 2017 ACR/ARHP Annual Meeting
Prediction of Fibrosis Progression in Systemic Sclerosis By Collagen Biomarkers
Rucsandra Dobrota¹, Suzana Jordan², Pernille Juhl³, Britta Maurer⁴, Lukas Wildi⁴, Anne-C. Bay-Jensen⁵, Morten Karsdal⁶, Anne Sofie Siebuhr⁷ and Oliver Distler², ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Nordic Bioscience, Herlev, Denmark, ⁴Department of Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, Herlev, Denmark
Background/Purpose: Altered extracellular matrix (ECM) remodeling leading to fibrosis is a key pathogenic process in systemic sclerosis (SSc). We previously showed that collagen formation and…
Abstract Number: 1268 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Bone Loss in Juvenile-Onset Systemic Lupus Erythematosus: A Prospective Study
Luiz A Sousa¹, Juliane Paupitz¹, Nadia E Aikawa², Liliam Takayama¹, Valéria F. Caparbo¹ and Rosa M R Pereira³, ¹Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JoSLE) is associated with low bone mass for age and fractures, nevertheless risk factors and predictors of bone involvement are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].